MeiraGTx is a gene therapy company, which is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The Company is pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. MeiraGTx is also developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration.
Net income (Q3, 2020)
EBIT (Q3, 2020)
Market capitalization (8-Jan-2021)
Closing stock price (8-Jan-2021)
|USD||Q2, 2018||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020||Q3, 2020|
Depreciation and Amortization
Cash From Operating Activities
MeiraGTx has 513 Twitter Followers. The number of followers has increased 0.4% month over month and increased 3.6% quarter over quarter
When was MeiraGTx founded?
MeiraGTx was founded in 2015.
Who are MeiraGTx key executives?
MeiraGTx's key executives are Keith R. Harris, Alexandria Forbes and Richard Giroux.
How many employees does MeiraGTx have?
MeiraGTx has 130 employees.
What is MeiraGTx revenue?
Latest MeiraGTx annual revenue is $13.3 m.
What is MeiraGTx revenue per employee?
Latest MeiraGTx revenue per employee is $102.2 k.
Who are MeiraGTx competitors?
Competitors of MeiraGTx include Caribou Biosciences, Editas Medicine and Evolutionary Genomics.
Where is MeiraGTx headquarters?
MeiraGTx headquarters is located at 7NQ 92 Britannia Walk, London.
Where are MeiraGTx offices?
MeiraGTx has offices in London, New York and Leiden.
How many offices does MeiraGTx have?
MeiraGTx has 3 offices.
Receive alerts for 300+ data fields across thousands of companies